Pandiella explained that the P-REX protein actives signaling mechanisms related to the system HER/ErbB contributing to the proliferation of breast cancer. “It is therefore a negative prognostic factor” said the researcher from CIC. According to Pandiella “breast patients who have P-REX are worse. This indicates that P-REX can be a therapeutic target not only for breast cancer, but for different types of cancer. “In fact he stated that his laboratory is in contact with a group of U.S. research to find out if pre-clinical models can be useful to discover new therapies.

About

Pandiella

Dr. Pandiella obtained his doctorate in medicine and surgery from the University of Santiago de Compostela. His scientific training includes four years as a researcher at the Ospedale San Raffaele of Milan and three years at Memorial Sloan Kettering Center in New York. From 1994 to 2001 he was part of the Microbiology Institute of Biochemistry, University of Salamanca. Currently, he is a researcher at the Institute of Molecular Biology of Cancer Cell (IBMCC) of the Cancer Research Center under the CSIC and the University of Salamanca. His research focuses on functional characterization of molecules involved in the genesis and progression of several human tumors, particularly breast tumors.